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Background: CXCR5þ T follicular helper (TFH) cells primarily promote B cells to produce an antigen-
specific antibody through germinal centers (GCs). TFH cells exist in circulation, and circulating(c) TFH2
cells, a subset of cTFH cells, are able to help naïve B cells produce IgE in healthy individuals. Conversely, IL-
10-producing regulatory B (Breg) cells inhibit an accelerated immune response.
Methods: We investigated the roles of cTFH cells and cBreg cells based on a TH2 response in patients with
atopic asthma (AA). Thirty-two patients with AA and 35 healthy volunteers (HV) were enrolled. We
examined cTFH cells including their subsets, their expression of ICOS and PD-1, and cBreg cells by flow
cytometry and their associations with clinical biomarkers. Plasma levels of CXCL13, which is a coun-
terpart of CXCR5, were also measured using ELISA.
Results: In patients with AA, cTFH2 cells were increased and cTFH1 cells were decreased compared with
those in HV. The expression levels of ICOS on cTFH and their subset cells were elevated and Breg cells
were greatly decreased. The plasma levels of CXCL13 in patients with AA were significantly elevated and
correlated well with the cTFH2/cBreg ratio. These cells were examined in 10 patients AA before and after
inhaled corticosteroid (ICS) treatment. Interestingly, the percentages and numbers of TFH2 and ICOSþ
cTFH cells declined after ICS treatment together with improvements in symptoms and clinical biomarkers.
Conclusions: The percentages and numbers of cTFH2 and ICOSþ cTFH cells might be useful as biomarkers
of TH2 typed airway inflammation in patients with AA.
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Introduction
Asthma is the most common chronic lung disease affecting
about 300 million people in the world. It has long been evident that
the severity of asthma varies greatly among patients, but this
phenotypic heterogeneity has recently been investigated in more
systematic ways. Cluster analyses of large numbers of highly
characterized individuals with asthma have shown that they can be
grouped into several phenotypic clusters.1e3 Allergic asthma, which
is one of these clusters, is based on type 2 immune responses to
allergens and other environmental factors, including type 2 helper
T (TH2) cell cytokine responses and production of IgE antibodies.
TH2-type CD4þ T cells and type 2 innate lymphoid cells (ILC2s),
which produce interleukin (IL)-4, IL-5 and IL-13 have been
considered major players in directing the pathophysiology of
allergic asthma, including airway eosinophilia, mucosal hyperpla-
sia, and airway remodeling.4,5
TH2 cells have been thought to play a critical role in allergic
asthma because they produce IL-4, a key cytokine that robustly
regulates IgE class switching. However, T follicular helper (TFH)
cells, which are a specialized subset of CD4þ Tcells, primarily help B
cells undergo class switch recombination (CSR), somatic hyper-
mutation (SHM) and affinity maturation through germinal center
(GC) reactions in lymphatic tissues. TFH cells express a chemokine
receptor of CXCR5, which facilitates their interaction with B cells,
and they secrete IL-4 and IL-21 to promote B-cell differentiation. In
GCs, TFH cells also express various costimulatory molecules
including inducible costimulator (ICOS) and programmed death 1
(PD-1) of an immune-regulatory molecule, and B cell lymphoma
(BCL)-6 as a transcription factors.6 It later became evident that
CD4þCXCR5þ T cells exist in human peripheral blood (circulating T
follicular helper cells; cTFH cells). These cells are classified into three
distinct subsets, TFH1, TFH2, and TFH17 cells, according to the
expression profiles of CXCR3 and CCR6. TFH1, TFH2, and TFH17 cells
secrete restricted repertories of cytokines such as interferon (IFN)-
g, IL-4, and IL-17, respectively, as do TH1, TH2 and TH17 cells.
Furthermore, TFH2 cells have the capacity to help naïve B cells
produce IgE and IgG.7,8 A recent study in mice suggested that TFH
cells, but not TH2 cells, initially induced by exposure to house dust
mites (HDMs) and produce IL-4 and promote the production of
HDMs-specific IgE from B cells in the GCs (sensitization phase) and
that upon re-exposure of HDMs (allergen), IL-4-committed TFH2
cells could differentiate into IL-4 and IL-13-double-producing TH2
cells that preferentially migrate to the affected allergic lesions of
lung (effector phase).9 These results indicate that IgE is produced as
a consequence of the cognate interaction between TFH cells and B
cells and that the plasticity between TFH cells and TH2 cells is closely
related to be the pathogenesis of allergic asthma. For these reasons,
TFH cells are considered to a key player in the specific immune re-
sponses underlying allergic inflammation. We have already re-
ported the skewing of circulating TFH2 cells in patients with allergic
rhinitis (AR) with or without asthma.10 Most cTFH cells are
considered to be central memory T cells except for some cTFH cells
that express ICOS and/or PD-1.8 These cTFH cells were compared
with GC TFH cells by gene profile, cytokine profile and functional
properties, and the results were almost the same as those for GC TFH
cells.11 Therefore, TFH cells derived from GC in LNs of the affected
lesion may be flowed into the circulating blood stream through
lymphatics.
On the other hand, there has been accumulating evidence
supporting a suppressive function of B cells. These B cells, which are
called regulatory B cells (Breg cells), can suppress immune re-
sponses in mice and humans.12,13 The absence or loss of these Breg
cells exacerbates disease symptoms in patients with allergic and
autoimmune diseases.14e17 A population of Breg cells showing
specific surface markers has not been reported, but several pop-
ulations showing different surface markers have been reported.18
Breg cells inhibit T cell-mediated immunity by producing IL-10,
IL-35 and TGF-b and inducing regulatory T cells (Treg) cells.12
Iwata et al. reported that CD24hiCD27þ B cells exhibited a regula-
tory function in human autoimmune diseases.19
Inhaled corticosteroid (ICS) administration is a most effective
treatment for asthma. In this study, to investigate the therapeutic
efficacy in cTFH cells based on TH2 response, we examined the
proportion and number of cTFH cells including their subsets and
expression of ICOS and PD-1 in patients with AA, and we also
compared patients before and after treatment patients with ICS
administration. CXCL13 is a counterpart for CXCR5 and their
expression in B and TFH cells is necessary for migration to B cell
follicles. Therefore, CXCL13 plasma level reported to be a marker of
the activity of GC reactions including the interaction between
antigen-presented TFH cells and B cells.20 We measured plasma
CXCR13 levels in patients with AA and HV. The proportion and
number of (IL-10-producing) CD24hiCD27þ cBreg cells, which
inhibit immune responses in patients with AA, were also investi-
gated. The results suggest the usefulness of cTFH cells as a
biomarker and therapeutic importance in patients with AA.
Methods
Study population
In this study, 32 AA patients and 35 HV were enrolled. The
characteristics of the patients with AA and HV are summarized in
Table 1. The diagnosis of AA was performed on the basis of the
Global Strategy for Asthma Management and Prevention, Global
Initiative for Asthma (GINA) 2017, 2018 and Japan Respiratory So-
ciety Guidelines.21 Subjects with AA were diagnosed by a ques-
tionnaire (asthma control questionnaire (ACQ),22 physical
examination, spirometry, airway reversibility and hyperreactivity
tests and measurements of specific IgEs and fractional exhaled ni-
tric oxide (FeNO). FeNO was measured by NIOX VERO (CHEST M.I.,
Tokyo, Japan). Serum levels of specific IgEs to allergens and non-
specific (total) IgE were measured by Immuno-CAP (Thermo
Fisher Scientific; Waltham, MA, USA). All of the patients with AA
had several or multiple specific IgEs to allergens. Seventeen of the
AA patients also had other allergic diseases such as AR, allergic
conjunctivitis, atopic dermatitis, pollen food allergy syndrome
(PFAS) and food allergy (Table 1). Ten patients with AA (three pa-
tients with mild AA, two patients with moderate AA and five pa-
tients with severe AA) were already being treated with an
ICS ± long -acting b2 agonist (LABA) ± leukotriene receptor
antagonist (LTRA) or other drugs, and the other 22 patients had a no
history of allergen-specific immunotherapy and had not been
Table 1
Characteristics of subjects.
Atopic asthma patients Healthy volunteers
(n ¼ 32) (n ¼ 35)
Age (years) 46.8 ± 16.0 43.8 ± 13.0
No.male/female 11/21 17/18
Smoking history never:19/ex:8/current:5
IgE (IU/ml) 654 ± 1404* 45 ± 54
Blood eosinophils (number/ml) 483 ± 752* 147 ± 120
FEV1% pred (%) 77.0 ± 18.6
FeNO (ppb) 63.2 ± 44.6
Other allergic complications AR; 14, AC; 4, PFAS; 2,
food allergy; 2
AR, allergic rhinitis; AC, allergic conjunctivitis; PFAS, pollen food allergy syndrome.
*p < 0.01. Mean ± SD.
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treated with drugs for three years prior to this study. None of the
HV had abnormal physical or chest X-ray findings and they were all
negative for the Immuno-CAP test. All of the subjects were non-
smokers. Written informed consent was obtained from all sub-
jects according to the Declaration of Helsinki. All of the protocols
were approved by the Institutional Review Boards of Sapporo
Medical University Hospital in Japan.
Antibodies
Panels of directly conjugated anti-human monoclonal anti-
bodies were used to measure lymphocyte species of TFH cells (anti-
CD3-APC, anti-CD4-APC-Cy7, anti-CD45RA-BV510 and anti-CXCR5-
PerCP-Cy5.5), TFH cell subsets (anti-CD3-FITC, anti-CD4-APC-Cy7,
anti-CD45RA-BV510, anti-CXCR5-PerCP-Cy5.5, anti-CCR6-APC, and
anti-CXCR3-PE-Cy7), TH2 subset (anti-CCR4-BV510), and activation
marker (antieICOSeBV421, anti-PD-1-PE) gated by cells negative to
anti-CD3-APC and Breg cells (anti-CD19-APC-Cy7, anti-CD24-
PerCP-Cy5.5, and anti-CD27-FITC) gated by cells negative to anti-
CD3-APC. These monoclonal antibodies were purchased from BD
Biosciences (San Jose, CA, USA).
Flow cytometry
Heparinized PBMCs were isolated from fresh blood specimens
by centrifugation over a discontinuous density gradient (Lympho-
lyte-H; Cedarlane, Burlington, ON, Canada). Cell staining and flow
cytometry using FACSCanto II (BD Biosciences) were performed as
previously described.23
ELISA
The Human CXCL13 Quantikine ELISA Kit obtained from R&D
Systems (Minneapolis, MN, USA) was used for the plasma samples
as described in the instructions.
Statistical analysis
All data are shown as means ± SD. Significant differences in
results were determined by using Student's t-test or the
ManneWhitney U test. Wilcoxon's rank sum test was used for
analysis of data before and after treatment. Correlations were
determined by Pearson's correlation coefficient. Probability values
less than 0.05 were considered significant.
Results
cTFH cells and their subsets in patients with AA and HV
First, we examined the percentages and absolute numbers of
cTFH (CD3þCD4þCD45RACXCR5þ) cells in all CD4þ T cells
(CD3þCD4þ) of patients with AA and HV (FACS procedure of cTFH
and other cTH cell subsets is shown in Fig. 1A and Supplementary
Fig. 1). The percentage and number in AA patients was signifi-
cantly larger than those in HV (AA, 20.7 ± 6.0%; HV,17.0 ± 4.1%, p¼
0.0038, and AA, 154 ± 70/ml; HV, 117 ± 45/ml, p ¼ 0.0127, Fig. 1B).
Interestingly, the percentage and absolute number of cTFH2 cells
in AA patients were further increased compared to those in HV
(AA, 41.6 ± 6.1%; HV, 34.0 ± 5.7%, p < 0.0001, and AA, 62 ± 24/ml,
HV; 39 ± 15/ml, p < 0.0001, Fig. 1C) and the percentage and ab-
solute number of TFH1 cells in patients with AA were conversely
decreased compared to those in HV (AA, 17.7 ± 5.3%; HV,
20.3 ± 5.8%, p ¼ 0.0524, AA, 28 ± 19/ml; HV, 24 ± 13/ml, p ¼ 0.2660,
Fig. 1C). The percentage and absolute number of TFH17 cells were
almost the same in the two groups. Therefore, the ratio of % TFH
2 cells to % TFH 1 cells was significantly elevated in AA patients
compared to that in HV (AA, 2.6 ± 0.9%; HV, 1.8 ± 0.6%, p ¼ 0.0001,
Fig. 1D).
ICOS and PD-1 expression on c-TFH cells and their subsets in patients
with AA and HV
We next assessed the expression of ICOS and PD-1 on cTFH cells
in patients with AA and HV (Fig. 2A). The expression was examined
in all AA patients and in 22 of the 35 HV in whom the expression
levels were measured. The percentages and absolute numbers of
ICOSþ and PD-1þ cTFH cells in AA patients were significantly
increased compared with those in HV (ICOSþ cTFH cells: AA,
9.1 ± 4.8%; HV 6.4 ± 2.7%, p¼ 0.0123 and AA,14 ± 10/ml, HV 7 ± 3/ml,
p ¼ 0.0010, PD-1þ cTFH cells: AA. 22.5 ± 7.7%; HVs, 16.3 ± 5.7%, p ¼
0.0014 and AA, 34 ± 16/ml, HV 18 ± 7/ml, p < 0.0001, ICOSþPD-1þ cTFH
cells: AA, 4.3 ± 2.9%; HV 2.7 ± 1.5%, p¼ 0.0109 and AA, 6 ± 5/ml, HVs
3 ± 2/ml, p ¼ 0.0011, Fig. 2B). We also examined the expression of
ICOS and PD-1 on cTFH cell subsets. The percentages and absolute
numbers of ICOSþ cTFH2 and cTFH1 cells in AA patients were much
larger than those in HV. The percentage of ICOSþ cTFH17 cells in AA
patients was higher, but not significantly higher, than that in HV,
but the absolute number was significantly lager in AA patients
(ICOSþ cTFH2 cells: AA, 8.4 ± 4.7%; HV, 6.0 ± 3.1%, p¼ 0.0248 and AA,
5 ± 4/ml, HV, 2 ± 1/ml, p ¼ 0.0001, ICOSþ cTFH1 cells: AA, 12.8 ± 7.6%;
HV, 8.5 ± 4.5%, p ¼ 0.0131 and AA, 4 ± 3/ml, HV, 2 ± 1/ml, p ¼ 0.0089,
ICOSþ cTFH17 cells; AA, 9.3 ± 6.3%: HVs 6.7 ± 4.4%, p ¼ 0.0906 and
AA, 5 ± 4/ml, HV 3 ± 2/ml, p ¼ 0.0301, Fig. 2C). In contrast, the per-
centages and absolute numbers of three subsets of PD-1þ cTFH cells
in AA patients were larger (but not significantly larger) than those
in HV except for the number of TFH2 cells (Supplementary Fig. 2).
The percentages and absolute numbers of subsets of ICOSþPD-1þ
cTFH cells were the same as those of subsets of PD-1þ cTFH cells
(data not shown). These results indicated that some cTFH cells,
especially cells with higher ICOS expression, were activated in pa-
tients with AA, whereas most of the cTFH cells are thought to be
quiescent.
cBreg cells in patients with AA
We then examined cBreg cells (CD3CD19þCD24hiCD27þ cells),
as negative regulators of immune response, in patients with AA
(Fig. 3A). The percentage and absolute number of cBreg cells in AA
patients were significantly smaller than those in HV (AA,
16.8 ± 9.4% and 25 ± 28/ml; HV, 30.2 ± 10.2% and 37 ± 22/ml,
p < 0.0001, Fig. 3B).
CXCL13 in patients with AA
The CXCL13-CXCR5 chemokine axis plays a major role in orga-
nizing both B cell follicles and GCs. Plasma CXCL13 has been shown
to be a biomarker of HIVþ patients who have broad antibodies to
HIV virus,20 and it has been reported that CXCL13 levels were
elevated in bronchio-alveolar lavage (BAL) fluid in AA patients24
and that IL-17 induced CXCL13 expression, which mediated B cell
infiltration in inflamed tissues of asthma patients.25 CXCL13 is a
counterpart of CXCR5 on TFH cells, and we therefore examined the
plasma CXCL13 levels in patients with AA by ELISA. CXCL13 levels
were measurable in 26 AA patients and 22 HV. The plasma levels of
CXCL13 in AA patients were significantly elevated compared to
those in HV (AA, 59.8 ± 41.9 pg/ml; HV, 39.4 ± 21.0 pg/ml, p ¼
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Fig. 1. Percentages and absolute numbers of cTFH cells and their subsets in patients with AA andHV. (A) Representative FACS profiles for TFH cells subsets in peripheral blood from patients
with AA and HV are shown. Numbers indicate percentage of cells in the gate. (BeD) Percentages and absolute numbers of cTFH cells and their subsets in patients with AA and HV.
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0.0369, Fig. 4A). Moreover, the plasma levels of CXCL13 in AA pa-
tients were significantly correlated to % cTFH2 cell/% cBreg cell
(cTFH2/cBreg) ratio (r ¼ 0.3993, p ¼ 0.0433, Fig. 4B). If this ratio is
assumed to be an immune balance maker between TFH2 cells under
the condition of an accelerated allergic response and Breg cells
having immune suppressive functions, these results indicate that
plasma CXCL13 level as a marker is affected by the TFH2 cell and
Breg cell balance.
Fig. 2. Percentages and absolute numbers of ICOSþ and/or PD-1þcTFH cells and their subsets of patients with AA and HV. (A) Representative FACS profiles for ICOSþ and/or PD-1þ TFH
cells subsets in peripheral blood from patients with AA and HV are shown. Numbers indicate percentage of cells in the gate. (B) Percentages and absolute numbers of ICOSþ and/or
PD-1þcTFH cells. (C) Percentages and absolute numbers of ICOSþcTFH subset cells.
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Relationships between cTFH cells and clinical biomarkers
The results of this study suggested that TFH 2 cell skewing with
activated TH2 response plays an important role in allergic airway
disease. Therefore, we investigated the relationship between TFH
2 cells and clinical markers. The serum total IgE level (based on TH2
response) was correlated with percentage of cTFH2 cells (IgE vs %
cTFH2 cells: r ¼ 0.4088, p ¼ 0.0202, Fig. 5A). And then, the absolute
number of cTFH2 and ICOSþ cTFH2 cells also showed significant
correlation to the level of FeNO, which is a biomarker of airway
eosinophilic inflammation in pretreated non-smoker patients with
AA (n ¼ 14, FeNO vs cTFH2 cells: r ¼ 0.5474, p ¼ 0.0427 and FeNO vs
ICOSþ cTFH2 cells: r ¼ 0.5783, p ¼ 0.0303, Fig. 5B). A possible reason
for this is that IL-4 produced by activated TFH2 cells may indirectly
affect airway eosinophilic inflammation. Forthermore, cTFH2 cells
exhibited the good correlation with the numbers of eosinophil in
examined AA patients (eosinophil vs cTFH 2 cells: r ¼ 0.4915, p ¼
0.0043, Fig. 5C). The results suggest that cTFH2 cell skewing may
play a role in IgE production and subsequently cause eosinophilic
inflammation in the allergic airway.
Change in cTFH cells and their subsets after asthma treatment
All of the patients with AA were treated by ICS ± LABA inhala-
tion, LTRA (and other drugs) according to the GINA guideline. The
percentage of cTFH cells, subsets of cTFH cells and cBreg cells were
determined in ten patients after treatments. These patients were
improved or remised by these treatments, especially by ICS
administration to airway. The ACQ scores and the FeNO levels were
significantly decreased, and the values of %FEV1.0 were increased
(Supplementary Table 1).
The percentage of cTFH cells was significantly increased after
treatment, but there was no difference in the percentage of cBreg
cells (data not shown) before and after treatment (Fig. 6A). The
percentage of cTFH2 cells was decreased (cTFH2 cells before treat-
ment: 41.4 ± 4.4%; cTFH2 cells after treatment: 37.8 ± 5.6%, p ¼
0.0284) and the percentage of cTFH1 cells was conversely increased
(cTFH1 cells before treatment: 15.9 ± 6.8%; cTFH1 cells after treat-
ment: 19.9 ± 7.8%, p ¼ 0.0190), and the ratio of %cTFH2 cells to %
cTFH1 cells was therefore significantly decreased after treatment
(cTFH2/cTFH1 ratio before treatment: 3.5 ± 2.6; cTFH2/cTFH1 ratio
Fig. 3. Percentage and absolute number of Breg cells in peripheral blood from patients with AA and HV. (A) Gating strategy for Breg cells in peripheral blood from patients with AA
and HV. Representative FACS profiles for Breg cells in peripheral blood from patients with AA and HV are shown. Numbers indicate percentage of cells in the gate. (B) Percentage and
absolute numbers of cBreg cells in patients with AA and HV.
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after treatment: 2.7 ± 2.8, p ¼ 0.0127) (Fig. 6B, C). These results
indicated that cTFH2 skewing was improved.
Next, we examined cTFH cells expressing ICOS and/or PD-1
(Fig. 7A). The percentage of ICOSþ cTFH cells was decreased after
treatment, but there was no difference in the percentage of PD-1þ
cTFH cells before and after treatment (ICOSþ cTFH cells before
treatment: 10.9 ± 6.2%; ICOSþ cTFH cells after treatment: 4.5 ± 2.0%,
p¼ 0.0069 and PD-1þ cTFH cells before treatment: 10.6 ± 8.8%; PD1þ
cTFH cells after treatment: 11.2 ± 7.0%, p ¼ 0.7643 and ICOSþPD-1þ
cTFH cells before treatment: 5.2 ± 3.1%; ICOSþ PD-1þ cTFH cells after
treatment: 3.2 ± 3.8%, p ¼ 0.0367, Fig. 7B). The expression of ICOS
was greatly decreased in all subsets of ICOSþ cTFH cells including c-
TFH17 cells (ICOSþ cTFH2 cells before treatment: 9.9 ± 6.2%; ICOSþ
cTFH2 cells after treatment: 4.1 ± 2.5%, p ¼ 0.0117 and ICOSþ cTFH1
cells before treatment: 16.5 ± 9.2%; ICOSþ cTFH1 cells after treat-
ment: 5.4 ± 3.0%, p ¼ 0.0077 and ICOSþ cTFH17 cells before treat-
ment: 12.5 ± 8.1%; ICOSþ cTFH17 cells after treatment: 3.5 ± 1.9%,
p ¼ 0.0077, Fig. 7C). The expression levels in all subsets of PD-1þ
cTFH cells, however, were not different after treatment
(Supplementary Fig. 3). The expression of ICOS on cTFH cells may be
related to the activity in the TH2-dominant airway inflammation in
patients with AA. The results indicate that the TH2-dominant and
activated TFH reaction in the asthmatic airway with its lymphatic
tissues was improved by the local ICS treatment and that this
improvement was related to the circulating profile of cTFH cells. It is
interesting that the change of TH2-dominant airway inflammation
is result in the change in profile of systemic TFH cell circulation.
cTFH2 and ICOSþ cTFH cells may be a useful marker of the activity in
TH2 and TFH2-dominant airway inflammation with BALT.
Discussion
In this study, we examined cTFH cells and their subsets in pa-
tients with AA in order to clarify the role of TFH cells based on TH2
response. We found that the percentage and absolute number of
cTFH cells and the expression levels of ICOS and PD-1 on cTFH cells
were increased in the patients with AA. We also found that the
percentage and absolute number of cTFH2 cells were increased
within the cTFH cell subset (TFH2 skewing) and that the percentage
of TFH2 cells was correlated with serum IgE level. The levels of
plasma CXCL13, which reflect GC activity, were increased in pa-
tients with AA compared with the levels in HV. On the other hand,
the percentage and absolute number of cBreg cells were decreased
in patients with AA compared with that in HV. Interestingly, the
plasma level of CXCL13 in patients with AAwas correlated with the
%cTFH2/%cBreg ratio. We also examined cTFH cells after treatment
with ICS (±LABA ± LTRA), and we found that cTFH2 skewing was
improved and the percentage of ICOSþ cTFH cells was decreased.
Thus, cTFH2 skewing toward normalization and decrease in acti-
vated cTFH cells, were related to local improvement of airway
inflammation based on TH2 reaction and clinical conditions.
The role of TFH cells is primarily helping B cells undergo CSR and
affinity maturation through GC reactions in lymphoid tissues. In
pathogenic conditions regarding infection, autoimmune disorder,
immune response to cancer, TFH cells play an important role
through induction of specific antibody production from B cells and/
or plasma cells.26 Recently, there have been some reports about the
cTFH cells in allergic diseases of human. We previously showed the
cTFH2 cell skewing in AR patients with or without asthma.10 Szabo
et al. reported the expansion of ICOSþPD-1þcTFH cells in patient
with childhood atopic dermatitis.27
The origin of human cTFH subset cells remains unknown. In
addition to the report by Locci et al.,11 He et al. showed that human
cPD-1þCCR7lo TFH cells rapidly differentiate into ICOSþPD-
1þmature TFH cells upon antigen encounter in order to promote
responses of antibodies and that they provide a biomarker to
monitor protective antibody responses during infection or vacci-
nation and pathogenic antibody responses in autoimmune dis-
eases.28 Moreover, in chronic SIV infection of rhesus macaques,
Velu et al. found that CXCR3(Th1)-TFH cells were dominant, that
there was no change in CCR4 (Th2)-TFH cells and that CCR6 (Th17)-
TFH cells were decreased compared to those in SIV negative rhesus
macaques in GC-TFH cells.29 The results obviously indicated the
existence of a subset of TFH cells in GCs like a subset of cTFH cells in
human. Thus, cTFH cells and their subsets including ICOSþ and/or
PD-1þ TFH cells may reciprocally influx and efflux from the follicles
including GC sites of affected lymphoid tissues to circulation.
We showed that percentage of cTFH2 cells was correlated with
serum IgE levels in patients with AA. There have been few evi-
dences between TFH cells and Ig production including IgE in human
inflamed lesions. Kamekura et al.23 reported infiltration of TFH cells
with high expression levels of ICOS and PD-1 in submandibular
glands of patients with IgG4-related disease (IgG4-RD). These TFH
cells also had a high expression level of Bcl-6 and helped B cells to
produce IgG4. Regarding cTFH cells in patients with AA, Gong et al.
reported that there was an increase in IL-4þIL-21þ cTFH cells and
that IgE production was accelerated in co-culture with CD19þ B
cells.30 On the other hand, other than the report by Ballesteros-Tato
et al., Kobayashi et al.,31 found that TFH cells in OVA -sensitized mice
supported the sustained production of IgE antibody in vivo in the
absence of other T cell lineages, even when TH2 cell function was
Fig. 4. Plasma CXCL13 levels in patients with AA and HV. (A) Plasma CXCL13 levels in
patients with AA and HV. (B) Correlation between plasma CXCL13 level in patients
with AA and ratio of %cTFH2 cells/%cBreg cells.
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severely compromised. Conditional deficiency of the master regu-
lator Bcl6 in CD4þT cells resulted in a marked reduction in TFH cells
and IgE antibody levels. We showed the cTFH2 cell skewing and
correlation between the TFH2 cells and serum levels of IgE, it is
speculated that TFH2 cells stimulated with allergic antigens were
activated and proliferated, accelerating IgE production frommature
B cells and PCs in allergic lung lymphoid regions, and some of these
TFH cells flowed into circulation.
The mechanism of human IgE production has not been fully
elucidated. Some mouse models have shown that IgE memory B
cells from GCs transiently disappear, except for IgE-producing
plasma cells, upon antigen recall, and IgG1 memory B cells
convert IgE memory B cells through CSR.32 On the other hand, it
was reported that there was local IgE production in bronchial and
nasal biopsy tissues from patients with asthma and AR.33,34 As a
result of CSR and SHM from IgM and IgG in these tissues, IgE is
produced from B cells. However, it is unclear whether these results
are responsible for TFH cells. Zang YeN et al. reported that IL-
4þCXCR5þCD4þ TFH cell count correlated with local IgE production
in a patient with chronic rhinosinusitis with a polyp. IL-4þBcl-
6þCD4þ TFH cells were identified in the ectopic lymphoid structure
in the polyp, and it was evident that TFH cells were involved in local
IgE production in the nasal polyp.35 It has been ethically difficult to
perform invasive biopsy of the airway with lymphoid tissues in
patients with AA, therefore, we need to elucidate the pathophysi-
ology in TFH cells of inflamed lesions using the BALF and induced
sputa in patients with AA.
As shown in Figure 3, cBreg cells in patients with AA were
greatly decreased compared to those in HV. Although the
mechanism of the decrease in Breg cells was not determined,
Van der Vlugt et al. showed that Breg cell was decreased and
caused dysfunction to lipopolysaccharide ex vivo in patients
with AA.36 Anchour et al. found that human IL-10 and TGF-b-
producing Breg cells controlled TFH cell maturation, increased
follicular regulatory T (Tfr) cells, and inhibited TFH cell-mediated
antibody secretion.37 These findings indicated that the cause of
accelerated TFH response in patients with AA may be partially
due to the substantial decline and dysfunction of Breg cells.
These facts indicate that an equilibrium between TFH cells and
Breg cells is very important, and therefor, %cTFH2/%cBreg ratio
may be a marker in disease activity of IgE-mediated allergic
diseases. This index was already used as significant correlations
with clinical data in ref. 10.
Except for HIV disease,20 there are some reports in autoimmune
diseases that there were elevated levels of CXCL13 in plasma or
serum and CXCL13 level showed the disease activity.38,39 Thus, our
result showing increased CXCL13 levels in patients with AA are
considered that TFH cells and B cells were infiltrated and interacted
Fig. 5. Relationships between cTFH2 cells and clinical biomarkers. (A) Correlation between %cTFH2 cells and serum IgE. (B) Correlation between the number of cTFH2 cells and FeNO
level, and between the number of ICOSþcTFH2 cells and FeNO level in patient with untreated and non-smoker patients with AA. (C) Corprelation between the number of cTFH2 cells
and blood eosinophiles.
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Fig. 6. Change in cTFH cells and their subsets after treatment. (A) Representative FACS profile indicating circulating CD3þCD4þCD45RACXCR5þ (cTFH) and their subsets cells before
and after treatment. (B) Change in cTFH cells before and after treatment. (C) Change in cTFH subset cells before and after treatment. (D) Change in %cTFH2/%cTFH1 subset cells before
and after treatment.
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in the B cell follicles of airways with BALT. It is reasonable that
plasma CXCL13 levels correlated well with the ratio of %cTFH2/%
cBreg in patients with AA, and it is possible that plasma CXCL13
level is also a biomarker of active TFH cells in TH2-mediated allergic
diseases. Our results are the first results for plasma CXCL13 levels in
patients with AA.
In our study, we found that cTFH2 skewing within cTFH cells was
improved and that ICOS expression declined with ICS
Fig. 7. Change in ICOSþcTFH cells and their subsets after treatment. (A) Representative FACS profile indicating CD3þCD4þCD45RACXCR5þICOSþcells before and after treatment. (B)
Change in ICOSþ and/or PD-1þcTFH cells before and after treatment. (C) Change in ICOSþcTFH subsets cells before and after treatment.
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administration. It has been reported that immunological disorder
involving TFH cells was improved by systemic administration of a
corticosteroid in patients with IgG4-RD.23,40 However, ICS admin-
istration in our patients with AAwas only by local inhalation to the
inflamed airway, and there would have been little corticosteroid
influx into blood stream and thus little systemic effect of the
corticosteroid. Nevertheless, local administration of ICS amelio-
rated airway TH2 inflammation including TFH cells with improved
symptoms and clinical biomarkers, interestingly, this result caused
change profile of cTFH cell. Measurement of cTFH2 and ICOSþ cells
may be useful as markers of allergic responses in patients with AA.
Indeed, blockade of ICOS signaling after allergic airway disease
establishment successfully depleted TFH cells, however, did not
affect the differentiation of other CD4þ T cell subsets in Balb/c
mice.41
Our study showed that ICOS expression, but not PD-1 expres-
sion, on c-TFH cells was down-regulated by treatment with ICS in
patients with AA. Upon antigen encounter, TFH cells express ICOS
and Bcl-6, and ICOS promotes the development and functions of TFH
cells into activated state.41,42 On the other hand, Shi et al. showed
that PD-1 inhibits the recruitment of TFH cells to follicles, promotes
TFH cell concentration through CXCR3 expression and the strin-
gency of GC affinity selection.43 Thus, there is a functional differ-
ence between ICOS and PD-1 in TFH cells, but they are essential for
the maintenance of TFH cell function. The different action between
ICOS and PD-1 expression by ICS treatment have been not deter-
mined. This will be investigated in a future study; however, PD-1
ligand and PD-1-related transcription factors of TFH cells may not
be influenced by corticosteroid action.
In conclusion, we demonstrated that the plasma CXCL13 levels
were elevated and were significantly correlated with the %cTFH2/%
cBreg ratio in patients with AA. Local treatment of the allergic
airway by administration of ICS results in improvement of cTFH2
skewing and decline in ICOSþ cTFH cells. cTFH cells and CXCL13 in
patients with AA may become useful biomarkers and therapeutic
targets in the future.
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